mirvetuximab soravtansine   Click here for help

GtoPdb Ligand ID: 12250

Synonyms: Elahere® | IMGN-853 | IMGN853 | M9346A-sulfo-SPDB-DM4 | mirvetuximab soravtansine-gynx
Approved drug
mirvetuximab soravtansine is an approved drug (FDA (2022))
Compound class: Antibody
Comment: Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC) that delivers the cytotoxic maytansinoid DM4 (a microtubule toxin) to cancer cells that express the folate receptor α (FOLR1; P15328) [2]. FOLR1 is an active oncology drug target [8]. Mirvetuximab soravtansine has proven particularly effective against FLOR1 +ve, advanced ovarian tumours [1,4,7].
The chemical structure of DM4 and its sulfo-SPDB linker is represented in PubChem CID 131704480.
Click here for help
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2022))
International Nonproprietary Names Click here for help
INN number INN
10176 mirvetuximab soravtansine
Synonyms Click here for help
Elahere® | IMGN-853 | IMGN853 | M9346A-sulfo-SPDB-DM4 | mirvetuximab soravtansine-gynx
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 575
Other databases
GtoPdb PubChem SID 473153838
Search PubMed clinical trials mirvetuximab soravtansine
Search PubMed titles mirvetuximab soravtansine
Search PubMed titles/abstracts mirvetuximab soravtansine